IGNAFIQUE Trademark

Trademark Overview


On Friday, March 9, 2018, a trademark application was filed for IGNAFIQUE with the United States Patent and Trademark Office. The USPTO has given the IGNAFIQUE trademark a serial number of 87828339. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 18, 2021. This trademark is owned by Eli Lilly and Company. The IGNAFIQUE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerat...
ignafique

General Information


Serial Number87828339
Word MarkIGNAFIQUE
Filing DateFriday, March 9, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 18, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 17, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 16, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, October 18, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 18, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, February 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 22, 2021EXTENSION 5 GRANTED
Thursday, February 18, 2021EXTENSION 5 FILED
Thursday, February 18, 2021TEAS EXTENSION RECEIVED
Tuesday, September 1, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 31, 2020EXTENSION 4 GRANTED
Monday, August 17, 2020EXTENSION 4 FILED
Monday, August 17, 2020TEAS EXTENSION RECEIVED
Wednesday, February 12, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 10, 2020EXTENSION 3 GRANTED
Monday, February 10, 2020EXTENSION 3 FILED
Monday, February 10, 2020TEAS EXTENSION RECEIVED
Saturday, July 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 25, 2019EXTENSION 2 GRANTED
Thursday, July 25, 2019EXTENSION 2 FILED
Thursday, July 25, 2019TEAS EXTENSION RECEIVED
Thursday, February 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 6, 2019EXTENSION 1 GRANTED
Wednesday, January 30, 2019EXTENSION 1 FILED
Wednesday, February 6, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 30, 2019TEAS EXTENSION RECEIVED
Tuesday, September 11, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 17, 2018PUBLISHED FOR OPPOSITION
Wednesday, June 27, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 13, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 12, 2018ASSIGNED TO EXAMINER
Friday, March 16, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 13, 2018NEW APPLICATION ENTERED IN TRAM